Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Dr Squatch price tag rumoured at $1.5bn in Unilever takeover

(Sharecast News) - The sale price of Unilever's takeover of men's grooming brand Dr Squatch is reported to have been $1.5bn, according to reports on Friday. The acquisition, from growth equity firm Summit Partners, was formally announced by all three companies on Monday, but press releases did not disclose any financial details.

While Unilever has said it will not reveal the terms of the deal, the Financial Times cited "several people familiar with the details" as saying the British consumer goods giant agreed to pay $1.5bn.

Dr Squatch, known for its natural soaps, body washes and deodorants with unique scents like wood barrel bourbon, and viral marketing campaigns with influencers and celebrities, "has grown to become a highly engaging men's personal care brand", Unilever said.

The brand's "culturally-relevant collaborations with limited-edition packs have helped to drive sales and grow a loyal consumer following on social media platforms and beyond".

Dr Squatch, which is primarily distributed in North America and Europe through digital commerce, retail and D2C channels, will be scaled internationally, according to Unilever.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.